Anne Harrington: It was interesting to see how some of those... how easily some of those experts moved into other areas. How somebody who might have been working on anthrax could enthusiastically dedicate a new career to tuberculosis. Or someone who might have worked on Ebola became a valued... partner of NIH, CDC, and FDA in investigating the evolution of wild measles, and looking at whether... you know our current vaccines aren't going to continue to be useful in combating measles in the future, and measles is of course now a global problem again. It was interesting to see that some of them could make that jump and be extremely effective in doing that.